Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Drug Transporters_ Patel

1,195 views

Published on

Drug Transporters
Although the knowledge regarding the conduct of transporters assays and data interpretation has expanded dramatically over the past years, in vitro-to-in vivo and preclinical-to-clinical translation of transport data is still a very challenging field.

With the draft EMEA guidance, the ITC whitepaper and FDA regulation under way, performing well-designed transporter experiments has become crucial for pharmaceutical companies.

  • Be the first to comment

  • Be the first to like this

Drug Transporters_ Patel

  1. 1. © Mike Kiev - Fotolia.com 2nd annual drug CliniCally relevant transporters Mechanistic modelling of transporter driven PK – Drug-drug interaction – Translation of transport data 12th – 14th April 2011 | Maritim pro Arte Berlin www.drug-transporters.com/SP Hear international case studies from • Improve your drug development programmes by applying effective testing and modelling leading companies and institutes: methodology for drug transporter activity • Sanofi-Aventis Deutschland • Learn how to conduct in vitro-to-in vivo and preclinical-to-clinical translation of transport data GmbH, Germany • Discuss the impact of regulatory authorities and the ITC whitepaper on drug transporter strategies • Capsugel, Division of Pfizer, Belgium • Benefit from recent studies from leading pharmaceutical and academic scientists • Gain full understanding of the role of drug transporters in toxicity • University of Tokyo, Japan • Genentech Inc., Member of HIGHlIGHTS the Roche Group, USA Ph.D. Tetsuya Terasaki, Ph.D. Reina Bendayan, • Dr. Margarete Fischer-Bosch Distinguished Professor Division of Professor and Associate Dean, Institute of Clinical Membrane Transport and Drug Targeting Graduate Education, Department of Pharmacology, Germany Department of Biochemical Pharmacology Pharmaceutical Sciences, Leslie Dan and Therapeutics, Graduate School of Faculty of Pharmacy, • Friedrich-Alexander-University Pharmaceutical Sciences, University of Toronto, Canada Erlangen-Nürnberg, Germany Tohoku University, Japan Ph.D. Maarten T. Huisman, • University of Manchester, UK Dr. Hiroyuki Kusuhara, DMPK Belgium, Teamleader PK-lab Associate Professor Department of Belgium & Leader J&J Center of • Newcastle University, UK Molecular PK, Expertise Transporters, • University of Heidelberg, University of Tokyo, Japan Johnson & Johnson, Belgium Germany INTERACTIvE WoRKSHoP DAy | Thursday, 14th April 2011 • University Halle-Wittenberg, Germany A Neurovascular Unit and Biochemical Barrier Function • University of Toronto, Canada B ABC of Modelling Transporter Data (I) - Principles and Practical Know How • Tohoku University, Japan C ABC of Modelling Transporter Data (II) - Applications and Combining In Vitro Knowledge with Clinical Observations • GlaxoSmithKline, UK D Species differences in drug transport and drug metabolism - do we have good • Johnson & Johnson, Belgium enough experimental models to work with? Media Partners Researched and developed by ry oo ur 11 y e 20 k b ua b o br ou th V ! Fe f y wi SA th s i 0,- 18 rd 29 th rly to € e Bi Ea upTo Register | T +49 (0)30 20 91 33 33 | F +49 (0)30 20 91 32 10 | E brijesh.patel@iqpc.de | www.drug-transporters.com/SP
  2. 2. 12th – 14th April 2011 | Maritim pro Arte Berlin Dear colleague, Sponsorship Since IQPCs first meeting on clinically relevant drug transporters in 2009 considerable progress has been We have a variety of packages made in understanding the influence of membrane transporters on drug absorption, disposition, metabo- available to suit your requirements. lism and elimination. Although the knowledge regarding the conduct of transporters assays and data inter- For all Sponsorship and Exhibition pretation has expanded dramatically over the past years, in vitro-to-in vivo and preclinical-to- opportunities call Neil Corteen: clinical translation of transport data is still a very challenging field. +49 (0)30 20 91 32 75 or email neil.corteen@iqpc.de. With the draft EMEA guidance, the ITC whitepaper and FDA regulation under way, performing well-designed transporter experiments has become crucial for pharmaceutical companies. So don´t miss IQPCs second conference For further information CliniCally relevant drug transporters please visit our website www.drug-transporters.com/SP or Mechanistic modelling of transporter driven PK – Drug-drug interaction – contact Brijesh Patel on Translation of transport data +49 (0)30 20 91 33 33 or email brijesh.patel@iqpc.de. 12th – 14th April 2011 | Maritim pro Arte Berlin which will bring together pharmaceutical and academic scientists. Areas of discussion will include: Team Discounts • Effective testing and modelling methodology We are offering attractive Team • In vitro-to-in vivo and preclinical-to-clinical translation of transport data Discounts, please contact us! • Impact of regulatory authorities and the ITC whitepaper We are looking forward to meeting you in Berlin. Kind regards Sebastian Krzonkalla Product Manager Media Partners PharmaVOICE magazine addresses the challenges and trends impacting the life-sciences industry. PharmaVOICEs subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers. www.pharmavoice.com www.PharmCast.com is the world leading website designed specifically for pharmaceutical, clinical and biotechnology professionals. www.Pharm Cast.com brings up-to-date information on pharmaceutical patents, FDA, news, jobs and Buyers Guide to our visitors. It was created and is maintained by pharmaceutical and biotechnology professionals. Visit www.PharmCast.com and discover for yourself why it is so popular among professionals. www.pharmcast.com G.I.T. Laboratory Journal Europe reports on all important topics relevant for the European laboratory market. Latest developments in analytics, technology, lab equipment, furniture and lab automation are displayed either in application notes from the chemical, food and pharmaceutical industry or in scientific articles. Bimonthly, G.I.T. Laboratory Journal Europe reaches 27,000 personalised addresses in industrial R&D and scientific institutions throughout Europe. www.laboratory-journal.com CHEManager Europe supplies managers and executives with essential market news, interviews to assist with decision-making, product applications and more. Leading personalities from the areas of scientific research, business and politics express their positions on current topics. All of this enables CHEManager Europe to establish itself as an image vehicle for the Chemical and Life Science industries. With a circulation of 15,000, CHEManager Europe is the most effective medium for this target group. Please note, the German market can be accessed through the German sister publication CHEManager, which is the leading publication (circulation: 43,000) in Germany for this market! www.chemanager-online/enTo Register | T +49 (0)30 20 91 33 33 | F +49 (0)30 20 91 32 10 | E brijesh.patel@iqpc.de | www.drug-transporters.com/SP
  3. 3. CoNFERENCE DAy oNE | Tuesday, 12th April 2011 09:00 Registration & coffee 13:15 Networking luncheon 09:30 Chairman´s welcome and opening address 14:15 Glial Cells: Secondary Barriers to Drug Permeability H ig hl Ph.D. Maarten T. Huisman, • Contribution of glial cells to the neurovascular unit ig ht DMPK Belgium, Teamleader PK-lab Belgium & Leader barrier function J&J Center of Expertise Transporters, • Localization and functional expression of ATP-Binding Johnson & Johnson, Belgium Cassette (ABC) membrane transporters in glial cells (astrocytes and microglia) Absorption • Regulation of ABC transporters by HIV viral coat protein, gp-120, in glial cells, a cellular target of HIV infection 09:45 The influence of drug transporters on drug absorption • Complexity of drug-transporter interactions in the • Relevant transporters in the gut context of HIV-associated inflammation and oxidative stress • uptake transporters Ph.D. Reina Bendayan, • Efflux Transporters Professor and Associate Dean, Graduate Education, Ph.D. Sven Stegemann, Department of Pharmaceutical Sciences, Leslie Dan Director Global Pharmaceutical Business Development Faculty of Pharmacy, Capsugel, Division of Pfizer, Belgium University of Toronto, Canada Distribution / Metabolism / Elimination 15:00 Impact of regulatory authorities and the ITC Whitepaper • Impact of FDA regulation • Impact of ITC Whitepaper 10:30 Human uptake and efflux transporters and their role in • Interpretation and application of the draft EMEA hepatic drug absorption, metabolism, and elimination – guidance Focus on lIvER • Japan • Relevance of transport proteins for drug half-life, uptake, Dr. Dietmar Weitz, and action Laboratory Head, MPK Metabolism & In vitro Systems, • Drug uptake into human hepatocytes by OCT and OATP Sanofi-Aventis Deutschland GmbH, Germany proteins • Drug efflux into bile / into the circulation by efflux 15:45 Refreshment break & networking transporters (e.g. MRP2, MRP4, MDR1 P-glycoprotein) • In vitro systems to measure uptake and efflux transporters Transporters & Toxicity • Pharmacogenetics of drug transporters PD Dr. Anne Nies, 16:15 Renal organic anion transporters: Is regulation of Head Membrane Transport Proteins, expression involved in renal damage after ischemia? Dr. Margarete Fischer-Bosch Institute of Clinical • OAT1 (Slc22a6) Pharmacology, Stuttgart • OAT3 (Slc22a8) University of Tübingen, Germany • Regulation of expression 11:15 Refreshment break & networking • Renal ischemia and reperfusion • Renal outcome 11:45 Focus on KIDNEy PD Dr. Christoph Sauvant, H ig Role of organic ion transporters in the renal elimination Laboratory Head, hl ig of drugs: clinical investigation using in vivo inhibitors ht University Halle-Wittenberg, Germany • In vivo inhibitors for OAT1, OAT3, MATE1 and MATE2-K • In vitro evaluation of transporter function using human 17:00 Closing remarks of the chairman kidney slices and brush border membrane vesicles and end of conference day one • Drug-drug interaction studies using probe substrates and inhibitors in healthy subjects • Endogenous substrates of renal organic ion transporters Dr. Hiroyuki Kusuhara, Associate Professor Department of Molecular PK, University of Tokyo, Japan 12:30 Drug Transport across the Blood-Brain Barrier (BBB) • Structure and function of the BBB • Regulation and Modulation of transporters • Models of the BBB • Drug Delivery Systems for CNS-delivery Prof. Dr. Gert Fricker, Director at the Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, GermanyTo Register | T +49 (0)30 20 91 33 33 | F +49 (0)30 20 91 32 10 | E brijesh.patel@iqpc.de | www.drug-transporters.com/SP
  4. 4. CoNFERENCE DAy TWo | Wednesday, 13th April 2011 08:30 Registration & coffee James Clarke, Scientist, DMPK, 09:00 Chairman´s welcome and opening address GlaxoSmithKline R&D, UK Ph.D. Sven Stegemann, Director Global Pharmaceutical Business Development 13:00 Networking luncheon Capsugel, Division of Pfizer, Belgium 14:00 Interplay of Metabolism and Transport in Determining oral Drug Absorption and Gut Wall Metabolism: Mechanistic Modelling of Transporter Driven PK & DDI A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model 09:15 Introduction into in vitro / in vivo models Amin Rostami-Hodjegan, Professor of Systems H ig • Overview of key in vitro / in vivo tools hl Pharmacology, ig • Advantages/Disadvantages ht School of Pharmacy and Pharmaceutical Sciences • IVIVC University of Manchester Ph.D. Maarten T. Huisman, Director of Scientific Development, DMPK Belgium, Teamleader PK-lab Belgium & Leader J&J Center of Expertise Transporters, Simcyp limited Blades Enterprise Centre Johnson & Johnson, Belgium 14:45 Development of a novel human proximal tubule cell Laurent Salphati, model to understand the renal handling of drug molecules Scientist, • We have developed a fully differentiated Human primary Genentech Inc., Member of the Roche Group, USA proximal tubule cell model • Cell monolayers exhibit vectorial transport of key 10:45 Refreshment break & networking prototypic substrates • We can quantify the contribution of individual 11:15 Transporter Pharmacoproteomics: Protein H transporters to the handling of drug molecules ig quantification for nonclinical and clinical research in hl ig the industry and the hospital • We can identify key sites of drug-drug interactions ht • Introduction: Why transporter protein quantification is • We can study transporter expression and function in important ? response to substrate exposure • Methodology: How to quantify transporter protein by LC- Dr Colin D A Brown Ph.D, Epithelial Research Group MS/MS ? (Detection limit, dynamic range, reproducibility) Institute for Cell & Molecular Bioscience, • Application Medical School, Newcastle University Quantitative evaluation of in vitro culture system based on the transporter protein quantification 15:30 Refreshment break & networking Quantitative evaluation of in vivo animal model based on the transporter protein quantification in mouse, 16:00 Modelling of Transporter Driven DDI monkey and human Reconstruction of in vivo brain distribution for several • uptaketransporter and exportpumps relevant for DDI drugs based on the mdr1a/MDR1 protein • hepatic and renal Transporters quantification at the BBB • In vitro analysis of DDIs Reconstruction of in vivo brain drug distribution in the • In vivo relevance of DDIs diseased animal model based on the mdr1a/MDR1 PD Dr. Jörg König, protein quantification at the BBB Institute of Experimental and Clinical Pharmacology Quantitative evaluation of drug efflux transporters in and Clinical Toxicology, the malignant glioblastoma and metastatic brain tumor Friedrich-Alexander-University Erlangen-Nürnberg, patients based on the transporter protein quantification Germany • Perspective Ph.D. Tetsuya Terasaki, Distinguished Professor, Division of Membrane Transport and Drug Targeting 16:45 Transporter investigations to explain mechanisms of Department of Biochemical Pharmacology and clinical DDIs Therapeutics, Graduate School of Pharmaceutical • Astrazeneca drug development cases Sciences, • Application of assays for uptake and efflux transporters Tohoku University • Preclinical-to-clinical translation of transporter data Johan Palm, PhD, 12:15 The mechanistic understanding and prediction of renal Clinical Pharmacology & DMPK, Mölndal, drug-drug interactions with methotrexate: An industry AstraZeneca R&D Mölndal, Sweden perspective • An introduction to the PK and ADME of methotrexate 17:30 outlook Transporters (with a focus on transporter mediated disposition) • Methotrexate drug-drug interactions, a mechanistic Ph.D. Maarten T. Huisman, understanding DMPK Belgium, Teamleader In Vitro Lab DMPK Belgium • Prediction of methotrexate drug-drug interactions using and Leader J&J´s Center of Expertise Transporters, in-vitro data from organic anion transporter assays Johnson & Johnson, Belgium • Gaps in our knowledge around methotrexate drug-drug interaction and how this is being addressed (includes 17:45 Closing remarks of the chairman PBPK modelling efforts) and end of conference day twoTo Register | T +49 (0)30 20 91 33 33 | F +49 (0)30 20 91 32 10 | E brijesh.patel@iqpc.de | www.drug-transporters.com/SP
  5. 5. INTERACTIvE WoRKSHoP DAy | Thursday, 14th April 2011 Workshop A 09:00 – 12:00 Neurovascular Unit and Biochemical Barrier Function Limited drug penetration is an obstacle that is often encountered in the treatment of CNS diseases including human immuno- deficiency virus type-1 (HIV-1) encephalitis (HIVE) and brain tumors. One mechanism that may contribute to this phenomenon is the expression of ATP-binding cassette (ABC) drug efflux transporters [i.e., P-glycoprotein (P-gp), Multidrug Resistance-Associated Proteins (MRPs/Mrps), Breast Cancer Resistance Protein (BCRP; also known as ABCG2)] at the blood-brain barrier (BBB). We have demonstrated that ABC transporters are not only expressed in brain microvessel endothelial cells which form the BBB but also in glial cells, the primary target of HIV infection in the brain. We propose that the localisation of these transporters in brain parenchyma may also contribute to the low accumulation and altered distribution of several therapeutic compounds including antiretroviral drugs and chemotherapeutic agents in the brain by creating a “secondary barrier” This workshop will discuss the . potential contribution of glial cells to the neurovascular unit barrier function and drug resistance in the context of HIV infection and cancer. Ph.D. Reina Bendayan, Professor and Associate Dean, Graduate Education Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada Workshop B 09:00 – 12:00 ABC of Modelling Transporter Data (I) - Principles and Practical Know How The session will give a step-by-step guide to enable participants in understanding the terms applied within modelling are- ana as applied to transporters. Transporter related experiments will be revisited and pitfalls will be highlighted to assist the researchers in finding their way through the complex datasets obtained via various in vitro techniques. All participants will have the opportunity of experiencing interactive problem solving sessions facilitated by experienced tutors. Workshop Lead: Amin Rostami-Hodjegan, Professor of Systems Pharmacology, School of Pharmacy and Pharmaceutical Sciences University of Manchester, UK Director of Scientific Development, Simcyp limited Blades Enterprise Centre, UK Worksop Tutors: Mr Matthew Harwood and Dr Fania Bajot, Research Scientists, Simcyp limited, Sheffield, UK Workshop C ABC of Modelling Transporter Data (II) - Applications and Combining In vitro Knowledge 13:00 – 16:00 with Clinical observations The session deals in details with complexity of the models related to transporters in gut and liver. The session touches upon transporter modelling in brain and kidneyi before desending to practical examples involving the applications of the modelling approach to answer observations related to oral bioavailability, hepatic clearance, drug-drug interactions (DDIs), and drug distribution to different organs. Impact of population variability and approaches to handling genetic variations are also discussed. Workshop Lead: Amin Rostami-Hodjegan, Professor of Systems Pharmacology, School of Pharmacy and Pharmaceutical Sciences University of Manchester, UK Director of Scientific Development, Simcyp limited Blades Enterprise Centre, UK Worksop Tutors: Mr Matthew Harwood and Dr Fania Bajot, Research Scientists, Simcyp limited, Sheffield, UK Workshop D Species differences in drug transport and drug metabolism - do we have good enough 13:00 – 16:00 experimental models to work with? What technologies should we be thinking of developing? • Humanised animal models • Computer PK-PD models • Primary in-vitro human cell models ( hepatocyte sandwich, proximal tubule monolayers) • Stem cell derived models? Dr Colin D A Brown Ph.D, Epithelial Research Group, Institute for Cell & Molecular Bioscience, Medical School, Newcastle UniversityTo Register | T +49 (0)30 20 91 33 33 | F +49 (0)30 20 91 32 10 | E brijesh.patel@iqpc.de | www.drug-transporters.com/SP
  6. 6. 4 Ways to Register Fax: +49 (0)30 20 91 32 10 Post: IQPC Gesellschaft für Management Konferenzen mbH Friedrichstraße 94 12th – 14th April 2011 | Maritim pro Arte Berlin 10117 Berlin, Germany Online: www.drug-transporters.com/SP If undeliverable, please return to: IQPC GmbH | Friedrichstraße 94 | D-10117 Berlin, Germany Email: brijesh.patel@iqpc.de For further information Phone: +49 (0)30 20 91 33 33 BOOKINGCODE Brijesh Patel #GTS/BPA Venue and Accommodation Maritim pro Arte Berlin Friedrichstraße 151 10117 Berlin, Germany Tel.: +49 (0)30 2033 4414 Fax: +49 (0)30 2033 4090 Email: reservierung.bpa@maritim.de yOUR DETAILS: PLEASE CONTACT OuR DATABASE MANAGER (VERTEILER@IQPC.DE) AND INFORM THEM OF ANy INCORRECT DETAILS WHICH WILL BE AMENDED ACCORDINGLy www.maritim.de Early Bird Conference Packages Standard Price Accommodation: A limited number of reduced rate rooms (Book and pay by the 18th February 2011) Platinum Package are available at the conference hotel. Accommodation can Save € 290,- € 2.609,- +VAT € 2.899,- + VAT 2 day conference plus 2 workshops be booked by calling the central reservation number. Gold Package 2 day conference plus 1 workshop Save € 260,- € 2.339,- +VAT € 2.599,- + VAT Please always quote the booking reference IQPC-Berlin. Bronze Package Hotel accommodation and travel costs are not included 2 day conference € 2.199,- + VAT in the registration fee. Workshop Day € 1.399,- + VAT Please indicate choice of workshop on Thursday, 14th April 2011 Workshop A I Workshop B I Workshop C I Workshop D For further information please A: Neurovascular Unit and Biochemical Barrier Function visit our website www.drug-transporters.com/SP B: ABC of Modelling Transporter Data (I) - Principles and Practical Know How or contact Brijesh Patel on C: ABC of Modelling Transporter Data (II) - Applications and Combining In Vitro Knowledge with Clinical +49 (0)30 20 91 33 33 or email brijesh.patel@iqpc.de. Observations D: Species differences in drug transport and drug metabolism - do we have good enough experimental models to work with? Only one discount applicable per person. Team Discounts CANT MAKE IT TO THE CONFERENCE? PURCHASE THE 2-DAy CONFERENCE DOCUMENTATION FOR € 595,- +VAT. Delegate Details Please fill out in Capitals! We are offering attractive Team Discounts, please contact us! DELEGATE Mr Mrs Ms Dr Family Name First Name Payment Terms Position Email Payment is due within 2 weeks after receipt of the Telephone Fax invoice. Organisation Address Cancellations and Substitutions CANCELLATIONS AND SUBSTITUTIONS DELEGATES MAy BE SuBSTITuTED AT ANy TIME. IQPC GESELLSCHAFT FüR Postcode/Town MANAGEMENT KONFERENzEN MBH DOES NOT PROVIDE REFuNDS FOR CANCELLATIONS. HOWEVER, SAVE WHERE WRITTEN NOTICE OF CANCELLATION Approving Manager: IS RECEIVED MORE THAN SEVEN (7) DAyS PRIOR TO THE CONGRESS, A CREDIT TO THE VALuE PAID AT THAT DATE WILL BE ISSuED, WHICH MAy BE uSED Signature AGAINST ANOTHER IQPC GMBH CONGRESS FOR uP TO ONE yEAR FROM ITS DATE OF ISSuE. FOR CANCELLATIONS RECEIVED SEVEN (7) DAyS OR LESS I agree to IQPC Gesellschaft für Management Konferenzen mbH payment terms. PRIOR TO AN EVENT (INCLuDING DAy SEVEN), NO CREDIT WILL BE ISSuED. IN THE EVENT THAT IQPC GMBH CANCELS AN EVENT, PAyMENTS RECEIVED AT yes, I would like to receive information about products and services via email. THE CANCELLATION DATE WILL BE CREDITED TOWARDS ATTENDANCE AT A FuTuRE IQPC GMBH CONGRESS OR, IN THE EVENT OF A POSTPONEMENT By Payment Methods IQPC GMBH, A RESCHEDuLED DATE. IF THE DELEGATE IS uNABLE TO ATTEND THE RESCHEDuLED EVENT, THE DELEGATE WILL RECEIVE A CREDIT IN LIEu PAy By BANK TRANSFER qUOTING REFERENCE DE18214.002: OF PAyMENTS MADE TOWARDS A FuTuRE IQPC GMBH EVENT, VALID FOR IQPC Gesellschaft für Management Konferenzen mbH, ONE yEAR FROM THE DATE OF ISSuE. IQPC GMBH IS NOT RESPONSIBLE FOR ANy LOSS OR DAMAGE AS A RESuLT OF A SuBSTITuTION, ALTERA- HSBC Trinkaus & Burkhardt AG, BLz 300 308 80, Konto-Nr. 430076019 TION, POSTPONEMENT OR CANCELLATION OF AN EVENT DuE TO CAuSES IBAN: DE32 30030880 0430076019, SWIFT-BIC: TuBDDEDD BEyOND ITS CONTROL INCLuDING, WITHOuT LIMITATION, NATuRAL DISAS- TERS, SABOTAGE, ACCIDENT, TRADE OR INDuSTRIAL DISPuTES OR HOSTILITIES. By CREDIT CARD: Please debit my credit card yOUR DETAILS PLEASE CONTACT OuR CuSTOMER SERVICE MANAGER (TEL: +49 (0)30 20913330 OR VERTEILER@IQPC.DE) AND INFORM THEM OF ANy INCORRECT DETAILS Card No WHICH WILL BE AMENDED ACCORDINGLy OR IF yOu PREFER NOT TO GETConference code DE18214.002 / INFORMATION PER FAx EMAIL OR PHONE ANyMORE. SPEAKER CHANGES Expiry date Security code OCCASIONALLy IT IS NECESSARy FOR REASONS BEyOND OuR CONTROL TO ALTER THE CONTENTS AND TIMING OF THE PROGRAMME OR THE IDENTITy OF Cardholder’s name THE SPEAKERS. DATA PROTECTION Signature PERSONAL DATA IS GATHERED IN ACCORDANCE WITH THE DATA PROTECTION ACT 1998. yOuR DETAILS MAy BE PASSED TO OTHER COMPANIES WHO WISH TO COMMuNICATE WITH yOu OFFERS RELATED TO yOuR BuSINESS ACTIVITIES. IF yOu DO NOT WISH TO RECEIVE THESE OFFERS, PLEASE TICK THE BOx BELOW. Card billing address (if different from Company address) PLEASE DO NOT PASS My INFORMATION TO ANy THIRD PARTy. By CHEqUE: Made payable to IQPC Gesellschaft für Management Konferenzen mbH © IQPC GESELLSCHAFT FüR MANAGEMENT KONFERENzEN MBH

×